Global Health Ventures appoints Lola Maksumova COO
This article was originally published in Scrip
Global Health Ventures, a speciality pharmaceutical company with a focus on sublingual drug delivery, has appointed Dr Lola Maksumova senior vice-president and chief operating officer. Dr Maksumova was previously vice-president of drug development at Pacific Therapeutics.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.